An interventional study of Vitamin D3 in Cytokine Storm, sponsored by Applied Science Private University. Completed at 1 site in Jordan. Open to participants aged 30 Years to 66 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-03-09.
Sponsored by Applied Science Private University · Not applicable, Interventional, and Prevention
The effect of Weekly 50,000 IU vitamin D3 supplements on the serum levels of selected cytokines involved in cytokine storm of Covid-19; A randomized clinical trial in the Covid-19 uninfected people with vitamin D deficiency.
No data are available on the effect of Weekly 50,000 IU vitamin D3 supplements on the serum levels of selected cytokines involved in cytokine storm of Covid-19 in the Covid-19 uninfected Jordanian people with vitamin D deficiency. This study was designed to investigate whether a high dose of vitamin D3 (50,000 IU) / week for 8 weeks supplementation has a potential effect on cytokine storm of Covid-19; such as IL-1 beta, IL-6, and TNF in the Covid-19 uninfected Jordanian people with vitamin D deficiency.
This study aims to assess whether high doses of vitamin D3 may improve immune responses against COVID-19 infection in uninfected Jordanian peoples. We hypothesize that Weekly 50,000 IU vitamin D3 supplements will significantly change immune responses compared with the control group.
133 studies on the registry are indexed under Cytokine Release Syndrome; 29 are open to participants now.
This study's enrollment of 100 is above the median of 48 across 95 interventional studies indexed under Cytokine Release Syndrome.
Browse Cytokine Release Syndrome studies →Applied Science Private University is the lead sponsor of 19 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Age ≥30 years old Male and female Jordanian ASU students and employees who live in Amman. Informed written consent from the participant prior to the start of the study. a serum 25(OH)D concentration less than 30 ng/mL.
Exclusion Criteria:
Any eligible subject refuses to apply with informed written consent before the start of the study. Men or women previously diagnosed with chronic diseases, including kidney disease or GIT problems. Who are receiving vitamin D3 supplements (3 months before the start of the study). Pregnant, Breastfeeding females, Females using hormonal contraceptives
Dietary Supplement: Dietary Supplement: Vitamin D3 Dietary Supplement: Vitamin D3 (50,000) IU / week for 8 weeks Other Names: cholecalciferol,
Dietary Supplement: Vitamin D3
Control group No intervention was given
Dietary Supplement: Vitamin D3 (50,000) IU / week for 8 weeks
Also known as: cholecalciferol
IL-1 beta
seum levels
Time frame: 8 weeks
IL-6
serum levels
Time frame: 8 weeks
TNF
serum levels
Time frame: 8 weeks
serum concentrations of 25-hydroxyvitamin D
ng/ml
Time frame: 8 weeks
lipid profile parameters
seum levels
Time frame: 8 weeks
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Applied Science Private University